Ding Xihui, Zheng Yingying, Liu Min, Lai Fu, Liu Shiqi, Chen Qiuping, Zhu Zihao, Liu Huanzhong, Li Xiaohui, Xu Jinyong, Wang Rui, Ren Zhenhua
Department of Anatomy, Anhui Medical University, Hefei, Anhui, China.
Second Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Cancer Med. 2025 Sep;14(17):e71179. doi: 10.1002/cam4.71179.
Pancreatic cancer (PC) is a common malignant tumor with high morbidity and mortality and a very poor prognosis, highlighting the urgent need to identify molecular therapeutic targets. Monocyte chemotactic protein-inducible protein-1 (MCPIP1) is a common inflammatory protein associated with the pathogenesis of a variety of cancers, although a comprehensive understanding of its function and the underlying mechanisms involved in PC remains unclear.
Immunohistochemistry, western blotting, immunofluorescence, flow cytometry, Transwell, and the scratch assay were used to evaluate the functional role of MCPIP1 in PC. Human PC samples, PC cells, and tumor tissues from subcutaneous tumors of nude mice were examined for MCPIP1 and a panel of epithelial-mesenchymal transition (EMT) -related indicators. In the mechanistic study, the IL6/JAK/STAT3 signaling pathway was investigated as a potential downstream pathway. IL6 activity was inhibited using the pharmacological inhibitor LMT-28 and was applied to MCPIP1 gene-deficient cells to assess the reversal of the malignant phenotype.
MCPIP1 was significantly downregulated in PC tissues and its expression strongly correlated with patient survival. MCPIP1 knockdown enhanced tumor cell stemness, proliferation, migration, and hybrid epithelial-mesenchymal transition (hybrid EMT) in PC cell lines, whereas overexpression suppressed these phenotypes. In xenograft models, MCPIP1 knockdown promoted tumor growth and hybrid EMT progression in mice. MCPIP1 knockdown activated the IL6/JAK/STAT3 signaling pathway, which was inhibited by MCPIP1 overexpression. LMT-28 treatment reversed the stemness and hybrid EMT phenotypes of MCPIP1-deficient cells.
MCPIP1 is a key regulator of PC progression, acting as a tumor suppressor by inhibiting the IL6/JAK/STAT3 signaling pathway. The findings suggest that MCPIP1 is a promising therapeutic target with potential implications for the development of new strategies for managing PC.
胰腺癌(PC)是一种常见的恶性肿瘤,发病率和死亡率高,预后极差,这凸显了识别分子治疗靶点的迫切需求。单核细胞趋化蛋白诱导蛋白-1(MCPIP1)是一种常见的炎症蛋白,与多种癌症的发病机制相关,尽管对其在PC中的功能及潜在机制的全面了解仍不清楚。
采用免疫组织化学、蛋白质印迹法、免疫荧光、流式细胞术、Transwell实验和划痕实验来评估MCPIP1在PC中的功能作用。对人PC样本、PC细胞以及裸鼠皮下肿瘤组织进行检测,以分析MCPIP1和一组上皮-间质转化(EMT)相关指标。在机制研究中,研究白细胞介素6/Janus激酶/信号转导子和转录激活子3(IL6/JAK/STAT3)信号通路作为潜在的下游通路。使用药物抑制剂LMT-28抑制IL6活性,并将其应用于MCPIP1基因缺陷细胞,以评估恶性表型的逆转情况。
MCPIP1在PC组织中显著下调,其表达与患者生存率密切相关。在PC细胞系中,敲低MCPIP1增强了肿瘤细胞的干性、增殖、迁移及混合上皮-间质转化(hybrid EMT),而过表达则抑制了这些表型。在异种移植模型中,敲低MCPIP1促进了小鼠肿瘤生长和hybrid EMT进展。敲低MCPIP1激活了IL6/JAK/STAT3信号通路,而过表达MCPIP1则抑制了该通路。LMT-28处理逆转了MCPIP1缺陷细胞的干性和hybrid EMT表型。
MCPIP1是PC进展的关键调节因子,通过抑制IL6/JAK/STAT3信号通路发挥肿瘤抑制作用。这些发现表明,MCPIP1是一个有前景的治疗靶点,对开发PC管理新策略具有潜在意义。